Founday (orforglipron), the new oral GLP-1 pill for weight loss, now available in the U.S. – Eli Lilly
Eli Lilly and Company announced that Foundayo (orforglipron) is now available to adults with obesity or overweight with weight-related medical problems following the FDA approval on April 1, 2026. When used alongside a reduced-calorie diet and increased physical activity, Foundayo helps individuals lose excess body weight and keep the weight off. Foundayo is a once-daily pill for weight loss that can be taken without food or water restrictions. People can now access Foundayo via LillyDirect and telehealth providers, with availability expanding to U.S. retail pharmacies beginning now.
“Foundayo delivers meaningful weight loss – an average of 27 pounds at the highest dose – and we made the path from prescription to doorstep as simple as possible,” said Ilya Yuffa, executive vice president and president of Lilly USA and Global Customer Capabilities. “Millions of Americans can now connect with a health care professional to determine if Foundayo is right for them and receive the medicine at their door through LillyDirect’s free home delivery, or access it through telehealth providers or local retail pharmacies.”
Foundayo is available starting at $149 per month at the lowest dose for self-pay patients. Eligible and commercially insured people with coverage for Foundayo may pay as little as $25 per month with the Foundayo savings card. Additionally, eligible Medicare Part D individuals may be able to get Foundayo for $50 per month, beginning July 1, 2026.
Supported by the rigorous ATTAIN clinical trial program, Foundayo was proven to help people lose weight and keep it off. In the ATTAIN-1 trial, individuals taking the highest dose of Foundayo and who stayed on treatment lost an average of 27.3 pounds (12.4%) compared to 2.2 pounds (0.9%) with placebo. Participants taking Foundayo, regardless of trial completion, lost an average of 25 pounds (11.1%), compared to 5.3 pounds (2.1%) with placebo. In the ATTAIN program, Foundayo also led to reductions in many markers of cardiovascular risk, including waist circumference, non-HDL cholesterol, triglycerides and systolic blood pressure across all doses.
Use of Foundayo with other GLP-1 receptor agonist medicines is not recommended. It is not known whether Foundayo is safe and effective for use in children. Foundayo may cause tumors in the thyroid, including thyroid cancer. Watch for possible symptoms, such as a lump or swelling in the neck, hoarseness, trouble swallowing or shortness of breath. If you have any of these symptoms, tell your health care provider. The most common side effects of Foundayo include nausea, constipation, diarrhea, vomiting, indigestion, stomach (abdominal) pain, headache, swollen belly, feeling tired, belching, heartburn, gas, and hair loss. These are not all the possible side effects of Foundayo.
Obesity Medicine Access
Obesity remains one of the few major chronic diseases without consistent insurance coverage across U.S. health plans. Even as new medicines transform treatment, approximately half of Americans with employer-sponsored insurance lack coverage for obesity management medications. As part of Lilly’s commitment to expanding obesity medicine access and improving affordability, Lilly has expanded self-pay access for individual patients.
About ATTAIN-1 and ATTAIN-2 clinical trial program
The ATTAIN Phase III global clinical development program for orforglipron has enrolled more than 4,500 people with obesity or overweight across two global registration trials.
ATTAIN-1 (NCT05869903) was a Phase III, 72-week, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of orforglipron at various doses to placebo in adults with obesity, or overweight with at least one of the following comorbidities: hypertension, dyslipidemia, obstructive sleep apnea or cardiovascular disease, who did not have diabetes. The trial randomized 3,127 participants across the U.S., Brazil, China, India, Japan, South Korea, Puerto Rico, Slovakia, Spain and Taiwan to receive various doses of orforglipron or placebo along with healthy diet and physical activity. The primary objective of the study was to demonstrate that orforglipron is superior to placebo in body weight reduction from baseline after 72 weeks.
ATTAIN-2 (NCT05872620) was a Phase III, 72-week, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of various doses of orforglipron with placebo in adults with obesity or overweight and type 2 diabetes. The trial randomized over 1,600 participants across the U.S., Argentina, Australia, Brazil, China, Czechia, Germany, Greece, India, South Korea and Puerto Rico to receive various doses of orforglipron or placebo along with healthy diet and physical activity. The primary objective of the study was to demonstrate that orforglipron is superior to placebo in mean body weight change from baseline at 72 weeks.
